



Announcement Summary

Entity name

IMAGION BIOSYSTEMS LIMITED

Date of this announcement

Friday December 17, 2021

The +securities the subject of this notification are:

☒ +Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
New class - code to be confirmed	6,000,000 FY21 Performance Options exercisable at \$0.0872, vesting and expiring on different terms.	6,000,000	14/12/2021
New class - code to be confirmed	1,500,000 Unlisted Options exercisable at \$0.0872, vesting monthly over 3 years varying expiry dates	1,500,000	14/12/2021
New class - code to be confirmed	9,000,000 FY21 Performance Rights vesting during a 4 year period subject to performance milestones.	9,000,000	14/12/2021

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

IMAGION BIOSYSTEMS LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ACN

Registration number

616305027

1.3 ASX issuer code

IBX

1.4 The announcement is

☒ New announcement

1.5 Date of this announcement

17/12/2021



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

☒ +Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

☒ does not have an existing ASX security code ("new class")



Part 3C - number and type of +securities the subject of this notification (new class) where issue has not previously been notified to ASX in an Appendix 3B

New +securities issued under an +employee incentive scheme**ASX +security code**

New class - code to be confirmed

+Security description

6,000,000 FY21 Performance Options exercisable at \$0.0872, vesting and expiring on different terms.

+Security type

Other

ISIN code**Date the +securities the subject of this notification were issued**

14/12/2021

Will all the +securities issued in this class rank equally in all respects from their issue date?☒ Yes**Were any of the +securities issued to +key management personnel (KMP) or an +associate?**☒ Yes**Provide details of the KMP or +associates being issued +securities.**

Name of KMP	Name of registered holder	Number of +securities
Yalia Jayalakshmi	Yalia Jayalakshmi	6,000,000

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.**Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms**

A summary of the terms of the Employee Incentive Scheme were provided in the Notice of Annual General Meeting announced to the ASX on 19 June 2020
<https://www.asx.com.au/asxpdf/20200619/pdf/44jsf59t4j96kz.pdf>

Any other information the entity wishes to provide about the +securities the subject of this notification

6,000,000 Options exercisable at \$0.0872, vesting and expiring:
-1,000,000 Options will vest if, during the 4 year period from 1 Dec 2021 to 30 Nov 2025, the Company secures decision enabling data package from a minimum 12-15 subjects enrolment in the phase 1 clinical study to enable Go/No Go development decision for the MagSense® HER2 product candidate; options will expire on 30 Nov 2025;
-1,000,000 Options will vest if, during the 4 year period from 1 Dec 2021 to 30 Nov 2025, the Company completes the



MH2TR Phase 1 study or submits a regulatory package in the US or EU or another country of interest to expand the current Phase 1 study; options will expire on 30 Nov 2025;
-1,000,000 Options vest on 30 Nov 2022, expire on 30 Nov 2027;
-1,000,000 Options vest on 30 Nov 2023, expire on 30 Nov 2028;
-1,000,000 Options vest on 30 Nov 2024, expire on 30 Nov 2029;
-1,000,000 Options vest on 30 Nov 2025, expire on 30 Nov 2030.
Vesting of the options is subject to continuous employment.

Issue details

Number of +securities

6,000,000

New +securities issued under an +employee incentive scheme

ASX +security code

New class - code to be confirmed

+Security description

1,500,000 Unlisted Options exercisable at \$0.0872, vesting monthly over 3 years varying expiry dates

+Security type

Other

ISIN code

Date the +securities the subject of this notification were issued

14/12/2021

Will all the +securities issued in this class rank equally in all respects from their issue date?

☒ Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

☒ No

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

A summary of the terms of the Employee Incentive Scheme were provided in the Notice of Annual General Meeting announced to the ASX on 19 June 2020



<https://www.asx.com.au/asxpdf/20200619/pdf/44jsf59t4j96kz.pdf>

Any other information the entity wishes to provide about the +securities the subject of this notification

1,500,000 Unlisted Performance Options exercisable at \$0.0872, vesting monthly over 3 years with varying expiry dates between 31 December 2024 and 30 November 2027. The vesting of the options is subject to continuous employment.

Issue details

Number of +securities

1,500,000

New +securities issued under an +employee incentive scheme**ASX +security code**

New class - code to be confirmed

+Security description

9,000,000 FY21 Performance Rights vesting during a 4 year period subject to performance milestones.

+Security type

Other

ISIN code**Date the +securities the subject of this notification were issued**

14/12/2021

Will all the +securities issued in this class rank equally in all respects from their issue date?

☒ Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

☒ Yes

Provide details of the KMP or +associates being issued +securities.

Name of KMP	Name of registered holder	Number of +securities
Yalia Jayalakshmi	Yalia Jayalakshmi	9,000,000

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.



Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

A summary of the terms of the Employee Incentive Scheme were provided in the Notice of Annual General Meeting announced to the ASX on 19 June 2020
<https://www.asx.com.au/asxpdf/20200619/pdf/44jsf59t4j96kz.pdf>

Any other information the entity wishes to provide about the +securities the subject of this notification

Vesting conditions:
-1,000,000 Performance Rights will vest if, during the 4 year period from 1 Dec 2021 to 30 Nov 2025, the Company submits a regulatory package (IND/IDE/CTA or equivalent) in the US or EU for investigational use of at least one product candidate;
-2,000,000 Performance Rights will vest if, during the 4 year period from 1 Dec 2021 to 30 Nov 2025, the Company obtains US or EU regulatory investigational use clearance to proceed to patient enrolment for at least one product candidate;
-2,500,000 Performance Rights will vest if, during the 4 year period from 1 Dec 2021 to 30 Nov 2025, the Company achieves a market capitalisation of at least \$250 million for a continuous period of at least 20 trading days; and
-3,500,000 Performance Rights will vest if, during the 4 year period from 1 Dec 2021 to 30 Nov 2025, the Company obtains regulatory agreement (FDA/EU or another country of interest) for a pivotal or phase 2b/3 protocol (such as FDA EOP2 meeting minutes).

Issue details

Number of +securities

9,000,000



For personal use only



Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this application, the +securities of the entity will comprise:

(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

4.1 Quoted +Securities (Total number of each +class of +securities quoted)

ASX +security code and description	Total number of +securities on issue
IBX : ORDINARY FULLY PAID	1,121,018,534
IBXOA : OPTION EXPIRING 28-APR-2023	233,501,933

4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
IBXAAD : OPTION EXPIRING 30-NOV-2026 EX \$0.14	1,000,000
IBXAAE : OPTION EXPIRING 30-NOV-2027 EX \$0.14	1,000,000
IBXAAF : OPTION EXPIRING 30-NOV-2028 EX \$0.14	1,000,000
IBXAW : OPTION EXPIRING 24-JUN-2024 EX \$0.028	2,150,000
IBXAX : OPTION EXPIRING 22-AUG-2024 EX \$0.06	300,000
IBXAY : OPTION EXPIRING 07-OCT-2024 EX \$0.06	200,000
IBXAZ : OPTION EXPIRING 20-SEP-2024 EX \$0.06	100,000
IBXAAA : OPTION EXPIRING 01-MAY-2026 EX \$0.028	3,250,000
IBXAAB : OPTION EXPIRING 01-MAY-2027 EX \$0.028	3,250,000
IBXAAC : OPTION EXPIRING 01-MAY-2028 EX \$0.028	2,000,000
IBXAE : PERFORMANCE RIGHTS	10,000,000
IBXAF : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	7,150,000



IBXAAG : OPTION EXPIRING 31-MAY-2029 EX \$0.115	200,000
New class - code to be confirmed : 6,000,000 FY21 Performance Options exercisable at \$0.0872, vesting and expiring on different terms.	6,000,000
New class - code to be confirmed : 1,500,000 Unlisted Options exercisable at \$0.0872, vesting monthly over 3 years varying expiry dates	1,500,000
New class - code to be confirmed : 9,000,000 FY21 Performance Rights vesting during a 4 year period subject to performance milestones.	9,000,000



Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

☒ Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

13